Hong Kong Treatment Services-Royal Postgraduate Medical School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. Clinical observations on adverse reactions.
D058186:Acute Kidney Injury / Q000139:chemically induced; D000293:Adolescent; D003523:Cycloserine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004417:Dyspnea / Q000139:chemically induced; D004977:Ethambutol / Q000008:administration & dosage / Q000627:therapeutic use; D005000:Ethionamide / Q000627:therapeutic use; D005334:Fever / Q000139:chemically induced; D005500:Follow-Up Studies; D006261:Headache / Q000139:chemically induced; D006801:Humans; D011696:Purpura, Thrombocytopenic / Q000139:chemically induced; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D011718:Pyrazinamide; D004977:Ethambutol; D003523:Cycloserine; D005000:Ethionamide; D012293:Rifampin